Earnings Releases·Nov 10, 2026, 4:07 PM ET

Metagenomi Therapeutics — Third Quarter 2026 Earnings Summary

Cash and marketable securities declined to $101.7 million as of September 30, 2026, from $160.8 million at year-end 2025, while total operating expenses decreased to $24.4 million for the quarter from $31.5 million in the prior period.
The Company reported a net loss of $21.1 million ($0.56 per share) for the quarter, compared to $20.4 million ($0.55 per share) in 2025, with collaboration revenue dropping to $2.2 million from $8.7 million in the same period last year.
The U.S. FDA cleared the Investigational New Drug (IND) application for lead program MGX-001, with the global INTEGR8 clinical trial planned to initiate in the first half of 2027 and initial safety data expected in the second half of 2027.
Management anticipates current cash reserves will support operations into 2028, though the quarter included a $1.2 million one-time net litigation settlement expense within general and administrative costs.